Despite its potential to worsen CTCL, treatment with monoclonal anti-tumor necrosis factor alpha (anti-tumor necrosis factor) antibody infliximab was started, resulting in a favorable intestinal response. The gene discussed is TNF; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.